NR3C2 and familial dilated cardiomyopathy: In DCM, anti-fibrotic therapy using angiotensin converting enzyme inhibitor (ACEi), angiotensin II receptor/neprilysin inhibitor (ARNI), sodium glucose co-transporter 2 inhibitor (SGLT2i) and mineralocorticoid receptor antagonist (MRA) could be also helpful to prevent progression of LV diastolic dysfunction.